Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) 78.3% HIGHER; received 510(k) clearance from the FDA to market its Microcyn Skin and Wound Gel as both a prescription and over-the-counter formulation.
CombinatoRx, Incorporated (NASDAQ: CRXX) 37.7% HIGHER; today reported positive results for its Phase 2 clinical study of CRx-401 as an add-on to metformin therapy in Type 2 diabetes.
Results from this trial demonstrated that CRx-401 (a synergistic combination of bezafibrate and diflunisal) performed statistically significantly better than bezafibrate on the primary...
Post new comment